Services

EnquBio's Comprehensive Drug Discovery Solutions & Services

At EnquBio, our expert team delivers high quality, efficient, and dependable R&D solutions that enable pharmaceutical and biotech partners to advance and expand their drug development pipelines.

Immunoassay Protein Quantification

Quantitative analysis of soluble and intracellular protein biomarkers using complementary immunoassay platforms.

EnquBio is a San Diego-based CRO providing MSD multiplex electrochemiluminescence (V-PLEX, U-PLEX and ultrasensitive S-PLEX), AlphaLISA, HTRF, LEGENDplex and ELISA services for quantifying cytokines, chemokines and soluble proteins in serum, plasma, supernatants, lysates and tissue-derived samples. As an MSD-listed CRO partner, our scientists select and customize the assay format around your analytes, species, matrix and expected concentration range.

MSD-Listed CRO Partner · View directory
Immunoassay protein quantification platform

What We Measure

From secreted proteins to pathway-specific intracellular signaling biomarkers.

Soluble Protein Biomarkers

Cytokines, chemokines and secreted proteins

Quantify treatment- and disease-associated changes in serum, plasma, cell culture supernatants, whole-blood-derived samples and other biological matrices.

Cytokines Chemokines Growth Factors Soluble Receptors Secreted Proteins PD Biomarkers
Intracellular Signaling Biomarkers

Defined pathway and phosphoprotein readouts

Quantify selected signaling events from cell or tissue lysates to characterize pathway activation, inhibition and pharmacodynamic response.

pERK pAKT pSMAD pSTAT p38 Total Protein

Multiple Platforms. One Fit-for-Purpose Strategy.

Different assays solve different problems. We select the format that best fits the biological question and study constraints.

MSD

Multiplex electrochemiluminescence
  • Multiplex cytokine and biomarker panels
  • Low-abundance analytes
  • Limited sample volume
  • Soluble and intracellular targets

AlphaLISA

Homogeneous luminescent immunoassay
  • Rapid protein quantification
  • High-throughput workflows
  • Miniaturized assay formats
  • Soluble and intracellular targets

HTRF

Homogeneous time-resolved fluorescence
  • Phosphoprotein signaling
  • Cell-based pathway analysis
  • Protein interactions
  • Screening and pharmacology studies

LEGENDplex

Flow cytometry-based multiplex immunoassay
  • Multi-analyte cytokine profiling
  • Immune biomarker panels
  • Limited sample volume
  • Flow-based multiplex detection

ELISA

Established single-analyte immunoassay
  • Focused biomarker measurements
  • Commercially established assays
  • Cross-study continuity
  • Custom or uncommon targets
We do not select a platform first. We select the assay strategy that best answers the biological question.

Choosing the Right Assay Format

Typical approaches vary by target, matrix, throughput and sensitivity requirements.

Study Need Typical Approach
Broad cytokine profilingMSD / LEGENDplex
Very low-abundance biomarkerMSD S-PLEX
High-throughput single-target quantificationAlphaLISA / HTRF
Phosphoprotein signalingMSD / AlphaLISA / HTRF
Focused single-analyte measurementELISA
Limited sample volumeMultiplex or miniaturized assay formats
Custom biomarker strategyPlatform selected based on assay requirements

Applications

Quantitative protein biomarkers can support both mechanistic and translational decision-making.

Immune & Inflammatory Profiling

Cytokines, chemokines, interferons, growth factors and immune-regulatory biomarkers.

Pharmacodynamic Biomarkers

Measure treatment-associated protein changes across concentration, dose and time.

Intracellular Signaling

Quantify phosphorylation and pathway responses following receptor activation or drug treatment.

Mechanism of Action

Connect compound activity to downstream protein and signaling responses.

Immuno-Oncology

Assess immune activation, suppression and tumor–immune signaling.

Autoimmune & Inflammatory Disease

Profile disease-relevant soluble and intracellular protein biomarkers.

Connect Signaling to Secreted Biomarkers

Protein biomarker analysis is most informative when interpreted in the context of the underlying pharmacology.

Treatment
Cellular Response
Intracellular Signaling
Secreted Biomarkers
Integrated Interpretation
For example, early pathway responses such as pERK or pAKT can be evaluated together with downstream cytokine release within the same experimental program.

Sample Types

Assay selection considers matrix effects, expected analyte abundance, available sample volume and study design.

Serum & Plasma
Cell Culture Supernatants
PBMC / Immune Cell Samples
Cell Lysates
Tissue Lysates / Homogenates
Whole Blood-Derived Samples

How We Design a Biomarker Study

The assay is selected around the biology, not the other way around.

01

Define the Biology

Clarify the pathway, mechanism, treatment response or translational question.

02

Select Biomarkers

Identify the soluble and/or intracellular biomarkers most informative for the study.

03

Select the Assay Format

Match platform choice to sensitivity, throughput, multiplexing, matrix and sample volume.

04

Generate & Interpret Data

Integrate quantitative biomarker results with pharmacology, dose, time and other study endpoints.

Frequently Asked Questions

Which MSD assay formats does EnquBio run?
We run V-PLEX validated panels, U-PLEX custom multiplex configurations and S-PLEX ultrasensitive assays on the MSD electrochemiluminescence platform, alongside AlphaLISA, HTRF, LEGENDplex and ELISA. If your analytes span multiple panels, we help configure the most sample- and cost-efficient combination.

How much sample does an MSD multiplex panel need?
A multiplex panel typically requires 25–50 µL of serum, plasma or supernatant per well, run in duplicate, with up to 10 analytes quantified from a single well. Exact volumes are confirmed at study setup.

How sensitive are MSD assays compared with ELISA?
MSD electrochemiluminescence typically offers a wider dynamic range and greater sensitivity than conventional ELISA, and S-PLEX assays extend detection to sub-pg/mL levels for low-abundance biomarkers.

Which species and sample types are supported?
Human, mouse, rat and non-human primate panels are available for most cytokine and chemokine targets. We routinely analyze serum, plasma, culture supernatants, cell lysates and tissue homogenates.

Does EnquBio operate under GLP?
No. EnquBio provides fit-for-purpose, exploratory bioanalysis for research and translational decision-making, which keeps studies fast and flexible. Data are intended for research use, not regulatory submission.

Have a biomarker question?

Send us your targets, matrix and study objective. Our scientists can recommend a fit-for-purpose assay strategy.

Contact Our Scientists →
Multiple complementary immunoassay platforms
Soluble and intracellular protein biomarkers
Integrated with in vitro, ex vivo and in vivo studies